Vivos Therapeutics annual stock-based compensation
2019
2020
2021
2022
2023
2024
2025
Vivos Therapeutics Stock-Based Compensation Growth & History (VVOS)
Vivos Therapeutics's stock-based compensation was $661,000 for fiscal 2025.
View full Vivos Therapeutics company overviewVivos Therapeutics annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $661,000 | −$101,000 | −13.25% |
| 2024 | 2024-12-31 | $762,000 | −$344,000 | −31.10% |
| 2023 | 2023-12-31 | $1.1M | −$1.3M | −53.84% |
| 2022 | 2022-12-31 | $2.4M | −$262,000 | −9.86% |
| 2021 | 2021-12-31 | $2.7M | $486,000 | +22.38% |
| 2020 | 2020-12-31 | $2.2M | $184,725 | +9.30% |
| 2019 | 2019-12-31 | $2.0M | — | — |
Vivos Therapeutics quarterly stock-based compensation
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $50,000 | −$192,000 | −79.34% |
| Q1 2026 | 2026-03-31 | $151,000 | −$166,000 | −52.37% |
| Q4 2025 | 2025-12-31 | $47,000 | −$10,000 | −17.54% |
| Q3 2025 | 2025-09-30 | $55,000 | −$87,000 | −61.27% |
| Q2 2025 | 2025-06-30 | $242,000 | −$28,000 | −10.37% |
| Q1 2025 | 2025-03-31 | $317,000 | $24,000 | +8.19% |
| Q4 2024 | 2024-12-31 | $57,000 | −$95,000 | −62.50% |
| Q3 2024 | 2024-09-30 | $142,000 | −$47,000 | −24.87% |
| Q2 2024 | 2024-06-30 | $270,000 | −$189,000 | −41.18% |
| Q1 2024 | 2024-03-31 | $293,000 | −$13,000 | −4.25% |
| Q4 2023 | 2023-12-31 | $152,000 | −$623,000 | −80.39% |
| Q3 2023 | 2023-09-30 | $189,000 | −$161,000 | −46.00% |
| Q2 2023 | 2023-06-30 | $459,000 | −$203,000 | −30.66% |
| Q1 2023 | 2023-03-31 | $306,000 | −$303,000 | −49.75% |
| Q4 2022 | 2022-12-31 | $775,000 | $312,000 | +67.39% |
| Q3 2022 | 2022-09-30 | $350,000 | −$763,000 | −68.55% |
| Q2 2022 | 2022-06-30 | $662,000 | $14,000 | +2.16% |
| Q1 2022 | 2022-03-31 | $609,000 | $175,000 | +40.32% |
| Q4 2021 | 2021-12-31 | $463,000 | −$363,069 | −43.95% |
| Q3 2021 | 2021-09-30 | $1.1M | $684,337 | +159.64% |
| Q2 2021 | 2021-06-30 | $648,000 | $82,627 | +14.61% |
| Q1 2021 | 2021-03-31 | $434,000 | $82,105 | +23.33% |
| Q4 2020 | 2020-12-31 | $826,069 | — | — |
| Q3 2020 | 2020-09-30 | $428,663 | — | — |
| Q2 2020 | 2020-06-30 | $565,373 | — | — |
| Q1 2020 | 2020-03-31 | $351,895 | — | — |
Vivos Therapeutics stock-based compensation trends
Over the last five fiscal years, Vivos Therapeutics's stock-based compensation decreased from $2.2M to $661,000, a change of −$1.5M. The latest reported quarter, Q2 2026, shows $50,000.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Vivos Therapeutics source filings ↗